drugset / Trial / NCT06331702
Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a phase IV, randomized, controlled, open-label study proceed in healthy children aged 8 months in China. The primary objective is to demonstrate the immunogenicity of simultaneous administration of JEV-I and MMR is not inferior to that of separate administration, as measured by seroconversion rates and antibody titers against the four antigens. The secondary objective is to describe the safety of the vaccines when administered simultaneously or separately.
Timeline
- Start
- 2024-03-02
- Primary completion
- 2025-02-11
- Completion
- 2025-02-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Measles-Mumps-Rubella Vaccine | Vaccine | 0.5 ml | Subcutaneous |
| Subject | Vero cell-drived inactive Japanese encephalitis vaccine | Vaccine | 0.5 ml | Intramuscular |